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Available online 31 March 2016Interstitial cystitis/bladder pain syndrome (IC/BPS) is a poorly understood syndrome affecting up to 6.5% of adult
women in the U.S. The lack of broadly accepted objective laboratorymarkers for this condition hampers efforts to
diagnose and treat this condition. To identify biochemical markers for IC/BPS, we applied mass spectrometry-
based global metabolite proﬁling to urine specimens from a cohort of female IC/BPS subjects from the Multidis-
ciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. These analyses identiﬁedmul-
tiple metabolites capable of discriminating IC/BPS and control subjects. Of these candidate markers, etiocholan-
3α-ol-17-one sulfate (Etio-S), a sulfoconjugated 5-β reduced isomer of testosterone, distinguished female IC/BPS
and control subjects with a sensitivity and speciﬁcity N90%. Among IC/BPS subjects, urinary Etio-S levels are cor-
related with elevated symptom scores (symptoms, pelvic pain, and number of painful body sites) and could re-
solve high- from low-symptom IC/BPS subgroups. Etio-S-associated biochemical changes persisted through 3–
6months of longitudinal followup. These results raise the possibility that an underlying biochemical abnormality
contributes to symptoms in patients with severe IC/BPS.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Urologic chronic pelvic pain syndrome (UCPPS) encompasses two of
the least understood syndromes in urology: interstitial cystitis/bladder
pain syndrome (IC/BPS) in females and chronic prostatitis/chronic pel-
vic pain syndrome (CP/CPPS) in males (van de Merwe et al., 2008). Fe-
male IC/BPS patients present with chronic pelvic pain, bladder/
urogenital discomfort, and urinary frequency or urgency symptoms. De-
spite its high prevalence (Berry et al., 2011), the pathophysiologic pro-
cesses underlying IC/BPS symptoms are poorly understood, and there
are no uniformly effective treatments (Hanno et al., 2015). Diagnosis
is often made based on exclusion of other conditions, and subjectiveus Disease Research, Box 8051,
ve., St. Louis, MO 63110, United
derson).
. This is an open access article underreports of symptoms. There are no pathognomonic pathologic or cysto-
scopic ﬁndings, or objective biomarkers for this syndrome (Hanno et al.,
2015). The absence of distinctive biochemical, neurological, or anatom-
ical explanations for IC/BPS, coupledwith a lack of objective biomarkers,
has led many to regard it as a functional somatic syndrome (Clemens,
2008).
There is a longstanding interest in identifying biochemical markers
of IC/BPS, both to facilitate diagnosis and to identify underlying
pathobiological mechanisms. Past studies have proposed a range of pu-
tative IC/BPS biomarkers, including antiproliferative factor (Erickson
et al., 2002), urinary phenylacetylglutamine (Fukui et al., 2009),
interleukin-6 and histamines (Lamale et al., 2006), urinary nerve
growth factor (Kim et al., 2014), Tamm–Horsfall protein-associated nu-
cleotides (Argade et al., 2013), and metabolites such as 2-oxoglutarate
(Wen et al., 2015). Recent advances in mass spectrometry based meta-
bolomics now raise the prospect that new biomarkers might be discov-
ered from among the hundreds to thousands of metabolite featuresthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient baseline demographics, continuous variables and metabolic characteristics. This
study examined forty IC/BPS female (with high symptom scores) and forty age-matched
non-IC/BPS (healthy) control female participants in the MAPP Research Network study.
Index Metric IC/BPS
(n = 40)
Non-IC/BPS
controls
(n = 40)
MAPP cohort
(n = 424)
Age (years) 37.7 ± 13.8 37.5 ± 13 43.4 ± 15.1
Duration of symptoms 12.5 ± 7.3 n/a 8.5 ± 10.6
ICSI IC symptom index 15.3 ± 3.0 0.2 ± 0.6 9.7 ± 4.7
ICPI IC problem index 13.3 ± 2.0 0.1 ± 0.5 8.5 ± 4.4
SYM-Q Pain in pelvic region
(0–10)
7.2 ± 1.4 0.0 ± 0.0 5.1 ± 2.2
Urgency (0–10) 7.4 ± 1.5 0.2 ± 0.6 5.1 ± 2.6
Frequency (0–10) 7.0 ± 2.0 0.1 ± 0.5 4.9 ± 2.6
Urological symptoms
(0–10)
7.5 ± 1.3 0.0 ± 0.0 5.2 ± 2.3
Non-urological pain
symptoms (0–10)
4.7 ± 3.0 0.4 ± 0.9 3.3 ± 2.7
GUPI Pain score (0–23) 18.0 ± 2.0 0.0 ± 0.0 12.6 ± 4.5
Total score (0–45) 36.5 ± 3.9 0.3 ± 1.0 25.6 ± 8.6
BPI Pain severity score
(0–10)
5.9 ± 1.4 0.1 ± 0.3 4.0 ± 2.0
# of pain sites checked
(0–45)
6.5 ± 2.2 0.1 ± 0.3 5.8 ± 6.5
AUASI Baseline symptom
score index (0–35)
26.3 ± 5.3 0.8 ± 1.1 15.5 ± 8.5
HADS Anxiety (0–21) 10.2 ± 4.9 2.7 ± 2.6 7.7 ± 4.5
Depression (0–21) 7.7 ± 5.0 1.0 ± 1.2 5.4 ± 4.7
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offers nuanced insights into the systemic biochemical shifts experi-
enced by patients, and can be linked to clinical metadata to reveal IC/
BPS-speciﬁc phenotypic effects.
Here, we used mass spectrometry based metabolomics approaches
to discover urinary biomarkers in IC/BPS females who underwent ex-
tensive urologic and non-urologic phenotyping in the Multidisciplinary
Approach to the Study of Chronic Pelvic Pain (MAPP) Research
Network's central clinical protocol, the Trans-MAPP Epidemiology and
Phenotyping Study (Landis et al., 2014; Clemens et al., 2014). Multiple
rounds of metabolomics discovery and validation revealed a IC/BPS-
associated urinary sulfometabolome proﬁle exempliﬁed by the
sulfoconjugated steroid etiocholan-3a-ol-17-one. This distinctive
sulfometabolome proﬁle persisted over one year of follow up in female
IC/BPS participants. These results reveal a shift in steroid metabolism
among IC/BPS females thatmay be useful for both diagnosis and for bet-
ter understanding the etiology of this debilitating illness.
2. Materials and Methods
2.1. Human Specimen Collection
All biological samples and clinical data investigated in this study
were collected as a part of the Multidisciplinary Approach to the Study
of Chronic Pelvic Pain (MAPP) Research Network(Clemens et al., 2014;
Landis et al., 2014), The MAPP Network is a multi-site research effort
sponsored by the National Institute of Diabetes and Digestive and Kid-
ney Diseases (NIDDK) that aims to investigate the disease characteris-
tics, phenotypes, and underlying biological mechanisms associated
with urologic chronic pelvic pain syndrome (UCPPS) (i.e., interstitial
cystitis/painful bladder pain syndrome [IC/BPS] and chronic prostati-
tis/chronic pelvic pain syndrome [CP/CPPS]). The central clinical proto-
col conducted by the MAPP Network is a longitudinal observational
examination of UCPPS termed the Trans-MAPP Epidemiology/Pheno-
typing Study (EPS). This involved extensive urologic and non-urologic
phenotyping, and collection of biological samples at baseline and at 6
and 12 month ofﬁce visits with intervening online data collection
(Landis et al., 2014). Participants who qualiﬁed for the EPS were
18 years of age or older, indicated a level of pain, pressure, or discomfort
in the pelvic region of at least 1 on a 0 to 10 scale, and had a diagnosis of
IC/BPS. Two types of controls were also recruited to provide symptom
data and biospecimens at baseline: 1) non-IC/BPS participants who re-
ported a 0 on the pain, pressure and discomfort scale, no chronic pain
in the pelvic or bladder region and chronic pain in at most one other
body region, and no urological symptoms, and 2) positive IC/BPS con-
trols who did not exhibit pelvic pain or urinary symptoms but had at
least one of 3 targeted comorbid non-urologic associated conditions
(Chronic Fatigue Syndrome, Irritable Bowel Syndrome, or Fibromyal-
gia). All participants provided informed consent. The institutional re-
view boards of the participating MAPP Network sites approved all
experimental procedures described in this manuscript, which conform
to standards indicated by the Declaration of Helsinki.
2.2. Patient Demographics and Disease Symptoms
Themidstreamurine samples (voided bladder 2, or VB2, representa-
tive of bladder contents) characterized in this study were derived from
female IC/BPS participants who reported high symptoms at the time of
their initial visit. Samples from non-IC/BPS participants were used as
negative controls for basis comparisons. IC/BPS females were classiﬁed
as high symptom based on the sum of the Genitourinary Pain Index
(GUPI) Pain and Urinary subscales, where included IC/BPS females had
a combined score ≥ 22. Symptommetricswere established by question-
naires that interrogated participants' pelvic and bladder symptoms,
pain symptoms, and severity of urologic condition (Table 1). Urologic
symptoms were assessed using the Genitourinary Pain Index (GUPI)(Clemens et al., 2009), Interstitial Cystitis Symptom Index (ICSI),
American Urological Association Symptom Index (AUASI), Brief Pain In-
ventory (BPI), Symptom and Health Care Utilization Questionnaire
(SYM-Q) and the Interstitial Cystitis Problem Index (ICPI) (O'Leary
et al., 1997). These indices include subscales for frequency and intensity
of pain, urgency and frequency of urination, and nocturia. Psychosocial
metrics were also assessed using the Hospital Anxiety and Depression
Scale (HADS) (Snaith, 2003).
2.3. Sample Preparation
Biospecimens were initially stored at 4 °C and moved to−80 °C. All
biospecimen shipmentswere on dry ice. Urine sampleswere thawed on
ice and centrifuged (23,000 g for 10min) at 4 °C. 200 μl of sample super-
natantwas dilutedwith 1 volumeHPLC grade H2O (Sigma), and ﬁltered
(MillexGP, 0.22mm)before analysis. Quality control (QC) sampleswere
prepared by pooling equal volume of each analyzed sample.
2.4. Liquid Chromatography–Mass Spectrometry (LC–MS)
Themass spectrometer used for this studywas an AB Sciex API 4000
QTrap (AB Sciex, Foster City, CA) operated in the negative ion
electrospray ionization (ESI) mode using the Turbo V ESI ion source.
The mass spectrometer was coupled to a Shimadzu UFLC (Kyoto,
Japan). Samples were injected onto an Ascentis Express fused core
phenyl-hexyl column (100 mm × 2 mm × 2.7 μm) with a ﬂow rate of
0.35 ml/min (Ascentis Express, Supelco). The gradient used was as fol-
lows: Solvent A (0.1% formic acid)was held constant at 98% and solvent
B (90% acetonitrile in 0.1% formic acid) was held constant at 2% for
1 min. Solvent B was increased to 35% by 23 min and then to 98% over
10min. The columnwas allowed to equilibrate for 3min before starting
the next run. The ion spray voltage was set to 5 kV. The heater temper-
ature was 600 °C. The declustering potential, nebulizer gas (G1), auxil-
iary gas (G2) and collision energy were set at −60, 45, 45 and -5 V
respectively. Full scan analysis was performed in the enhanced mass
spectrometry (EMS) mode using the electrospray ionization technique
with coverage of mass range: 50 to 1000 Da by using a scan rate of
1000 per minute, and the MS/MS screening was accomplished in the
combinational mode of EMS_IDA_EPS.
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To identify IC/BPS -associated molecular features, full scan or sulfate
precursor scan proﬁles from selected urinary specimens were aligned
and integrated using XCMS (Scripps) orMarkerView v1.2.0. Pareto scal-
ing of triplicate runs was used to identify differential biomarker expres-
sion among clinical subgroups. Unsupervised and discriminate principal
component analyseswere both performed inMarkerViewv1.2.0. Candi-
date ions were identiﬁed by PCA-DA loading plots and visually veriﬁed
in the mass spectra.
2.6. Etio-S Puriﬁcation and Identiﬁcation
To partially purify Etio-S from human urine, we used high perfor-
mance liquid chromatography (HPLC) on a Shimadzu Prominence
UFLC with a gradient of 0.1% formic acid to 90% acetonitrile + 0.1%
formic acid. Urine was fractionated on an Ascentis Express phenyl-
hexyl column (Supelco). Candidate-containing fractions, as determined
by liquid chromatography–tandem mass spectrometry (LC–MS/MS),
were further puriﬁed over a Kinetex C18 column (Phenomenex).
These enriched fractions were then analyzed on an Agilent 6550 Q-
TOF mass spectrometer to determine the accurate mass. Selected
analytes were characterized by MS/MS product ion scanning over a
range of collision energies. For targeted LC–MS/MS assays, the most in-
tense product ion peak(s) were selected with their corresponding opti-
mal collision energy. Further structural information was generated
using GC-EI-MS, whose mass spectra permitted the identiﬁcation of
etiocholan-3α-ol-17-one sulfate through spectral matching with the
NIST 14 spectral library. Subsequent conﬁrmation was accomplished
my conﬁrming identical GC retention time and mass spectrum with a
commercially available standard (Sigma).
2.7. Urinary Sulfate Neutral Loss Analysis
We used a UFLC-4000 QTRAP with the chromatography and ion
source settings described above to identify compounds with a common
neutral fragment loss of 97 m/z units. The collision energy was set to
35 V, and the ﬁrst mass analyzer (Q1) was set to scan fromm/z 100 to
1000 a.m.u., whereas the second mass analyzer (Q3) simultaneously
scanned at 97 m/z units less than Q1. Sensitivity was maximized by
selecting the low-resolution (2-a.m.u. window, 0.7 full-width at half-
height) setting. In this manner, only ions showing a neutral loss of
97 a.m.u. were detected.
2.8. Statistical Analysis
For between-group comparisons, we determined whether the re-
sponses were normally distributed by using the Shapiro–Wilk test.
When normally distributed, we used t-test for parametric, or Mann–
Whitney for non-parametric comparisons (Prism v.6.0d, GraphPad).
Principal component analysis-discriminant analysis (PCA-DA) and par-
tial lease squares-discriminant analysis (PLS-DA)were used for discrim-
inant analysis. Two-way analysis of variance (ANOVA) was performed
for multiple-group comparisons. Wilcoxon matched pairs signed rank
test was used for non-parametric paired longitudinal comparisons. Re-
ceiver Operator Characteristic (ROC) curves were used to evaluate
Etio-S levels in IC/BPS samples as predictive for subgroup 1 vs. subgroup
2 (SigmaPlot v. 12.3, Systat Software). These ROC curves were also used
to determine the threshold to maximize sensitivity and speciﬁcity.
3. Results
3.1. Participant Characteristics
To seek signature IC/BPS metabolites, we selected a well-
characterized group of female IC/BPS participants and controls enrolledin theMAPP Research Network (Landis et al., 2014) (referred to here as
the ‘discovery’ specimens) for metabolomic analysis. The 40 IC/BPS dis-
covery subjects selected in this study are females, had high symptom
scores (see Materials and Methods), and had urine specimens available
at enrollment. The non-IC/BPS control group consisted of 40 age-
matched female specimens (Table 1). IC/BPS females reported symp-
toms for 12.5 ± 7.3 years. At the time of initial evaluation, IC/BPS fe-
males reported a mean interstitial cystitis symptom index (ICSI) of
15.3 ± 3.0, and an interstitial cystitis problem index (ICPI) of 13.3 ±
2.0. They reported similarly high pelvic pain/pressure/discomfort rat-
ings (7.2 ± 1.4 on a 0 to 10 numeric rating scale), and the genitourinary
pain index (GUPI; 18.0 ± 2.0). These disease metrics are signiﬁcantly
lower for non-IC/BPS controls (Table 1). While 6/40 (15%) of both the
IC/BPS and control groups reported general medication usage, IC/BPS
participants reported additional central (19/40, 47.5%) and opioidmed-
ication usage (9/40, 22.5%).
3.2. The IC/BPS Patient Group Exhibits a Distinctive Urinary Metabolite
Composition
To determine whether there exist signature IC/BPS urinary metabo-
lites, we analyzed urine specimens from the discovery data set using liq-
uid chromatography-mass spectrometry (LC–MS) in both negative and
positive electrospray ionizationmodes (ESI, seeMaterials andMethods)
(Lv et al., 2011).We ﬁrst used unsupervised principal components anal-
ysis (PCA) to overview the metabolomics proﬁles for each discovery
specimen in the study cohort (Supplemental Fig. 1), followed by super-
vised PCA discriminant analysis (PCA-DA, Fig. 1a and b). While PCA
graphically displays overall metabolite variation differences between
all subjects, this analysiswas not clearly related to IC/BPS-speciﬁc differ-
ences. To identify metabolite variations that distinguish the two clinical
groups (IC/BPS and non-IC/BPS)we used PCA-DA. The resulting PCA-DA
plot indicates only partial overlap between IC/BPS and non-IC/BPS spec-
imens, consistent with a distinctive urinary metabolite pattern in some
IC/BPS subjects. To determine which metabolites contribute to this dis-
tinctive metabolite pattern, we conducted a loadings plot analysis (Fig.
1c). The loadings plot identiﬁed multiple metabolites that distinguish
IC/BPS subjects and therefore represent preliminary biomarker candi-
dates (Table 3).
Urinary Metabolites Distinguish Symptomatically Distinctive IC/BPS
Patient Subgroups
The PCA-DA plot of urinary metabolite proﬁles suggests the exis-
tence of two IC/BPS patient subgroups: subgroup 1, whosemetabolome
resembles non- IC/BPS controls, and subgroup 2, whose urinary metab-
olome is distinctive. The parameter that best distinguishes these two
subgroups' metabolomic differences is D1 loadings (the x-axis in
Fig. 1a). A single parameter created by PCA-DA, the D1 loadings value
quantiﬁes the variance in multiple interrelated metabolites that distin-
guish IC/BPS from non- IC/BPS subjects. Specimens whose D1 values
overlap non- IC/BPS controls (Fig. 1d) deﬁned subgroup 1 (19/40,
47.5% IC/BPS subjects). IC/BPS subjects whose D1 values did not overlap
non-IC/BPS controls deﬁned subgroup 2 (21/40, 52.5% IC/BPS subjects).
To determine whether these subgroups correspond to clinically mean-
ingful differences, we compared their disease activity scores. Symptom
and pain scores in IC/BPS subgroup 2 were signiﬁcantly higher than in
subgroup 1 (p-value b 0.05 for SYM-Q, GUPI, BPI, and AUASI scales,
Table 2). This association between urinary metabolomic proﬁle and
symptom characteristics suggests the existence of phenotypically dis-
tinctive IC/BPS patient subgroups with objective biochemical
differences.
3.3. Urinary Sulfoconjugated Etiocholan-3α-ol-17-One (Etio-S) is a Corre-
late of IC/BPS Subgroup Differences
To determine exactly which urinary metabolites and metabolite
class(es) distinguish IC/BPS subgroup 2, we used the D1 loadings plot
Fig. 1. PCA-DA distinguishes an IC/BPS participant subgroup by a) negative and b) positive ESI-MS. Score plots of PCA-DA analysis of urine from IC/BPS participants (red) were clustered
separately from non-IC/BPS controls (gray). Quality control samples (black) were prepared by pooling equal aliquots from each IC/BPS and non-IC/BPS sample, and run at random
intervals. Each data point represents the average of triplicate runs. (c) Loading plot of PCA components 1 and 2 determined by negative ESI-MS. (d) Distribution of values from the
loadings plot indicates two distinct subgroups within the IC/BPS population. The D1 loadings values resolve two distinct IC/BPS subgroups, with 19 out of the 40 (47.5%) samples in
subgroup 1 (red), and 21 out of the 40 (52.5%) in subgroup 2 (blue).
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for detailed chemical characterization. Among these, a molecule atm/z
369 (retention time 18min) corresponded to awell-resolved, highly re-
producible chromatographic peak with greater abundance in subgroup
2 specimens. Tomore precisely quantify thismolecule, we constructed a
targeted mass spectrometric assay (LC–MS/MS) and normalized the
molecule's peak intensity to that of an internally invariant urinary mol-
ecule with a similar m/z ratio and a retention time of 20 min. In this
assay, urinary levels of m/z 369 (18 min) discriminated (i) IC/BPS
from non- IC/BPS samples and (ii) IC/BPS subgroup 1 from subgroup 2
(p = 0.0003 and 0.0022, respectively, Fig. 2a). These results conﬁrm
the presence of a single urinary molecule (m/z 369, 18 min) identiﬁed
through metabolomic analyses that differentiates IC/BPS subjects (Fig.
2b). Analysis of variance comparing Etio-S levels between healthy,Table 2
Clinical characteristics discriminate the IC/BPS subgroups. IC/BPS subjects were divided
into two subgroups (1 and 2) based onmetabolic differences. These subgroups can be dis-
criminated on the basis of commonly used symptom scores (deﬁned below). Only the sta-
tistically signiﬁcant mean values and standard deviations of each metric are shown for
clarity.*
Index Metric Subgroup 1 Subgroup 2 p-Value
SYM-Q Non-urological pain symptoms
(0–10)
3.5 ± 2.7 5.7 ± 2.9 0.024
GUPI Pain score (0–23) 17.2 ± 1.7 18.7 ± 1.9 0.037
BPI # of painful sites checked (0–45) 9.5 ± 9.5 13.3 ± 9.4 0.043
AUASI Baseline symptom index (0–35) 24.3 ± 5.9 28.1 ± 3.9 0.038
CSQ Ability to decrease pain with
coping (0–6)
2.32 ± 4.2 2.95 ± 0.9 0.050
PANAS Negative affect (5–50) 24.24 ± 2.24 26.24 ± 0.24 0.042
⁎ SYM-Q—Symptom and Health Care Utilization Questionnaire; GUPI—Genitourinary
Pain Index; BPI—Brief Pain Inventory; AUASI—American Urological Association Symptom
Index; CSQ—Client Satisfaction Questionnaire; PANAS—Positive and Negative Affect
Schedule.subgroup 1 and subgroup 2 categories show that this correlation is sta-
tistically signiﬁcant (p b 0.005, ANOVA).
Next, we pursued chemical structure analysis of the IC/BPS
-associated molecule at m/z 369 (18 min). This molecule was stable
for HPLC puriﬁcation, and accurate mass analysis of a puriﬁed urinary
fraction yielded an m/z value of 369.1745,−2.18 ppm, corresponding
to the empiric formula C19H30O5S. MS/MS analysis of this ion yielded a
fragment atm/z 96.9597 (Fig. 2c). This distinctive negative ion fragmen-
tation is highly characteristic of a sulfate group (SO4H−) fragment from
a sulfated aliphatic molecule, which is distinct from them/z 80 loss as-
sociated with sulfated aromatic alcohols or enols (SO3) (Shields-Cutler
et al., 2015; Yi et al., 2006). The empiric formula and MS/MS spectrum
supported provisional molecular identiﬁcation as a sulfated androgen
isomer (androsterone, dihydrotestosterone, or etiocholanolone). To dis-
tinguish from among these isomers, the biomarker candidate was
sulfatase-treated and analyzed bygas chromatography–mass spectrom-
etry (GC–MS) as its trimethylsilyl (TMS) derivative. Spectral matching
of the electron ionization (EI) spectrum with the NIST14 mass spectral
library revealed etiocholan-3α-ol-17-one as the nearest match. This as-
signment was next conﬁrmed by comparison to a commercially avail-
able etiocholan-3α-ol-17-one standard (Fig. 2d). Together, these dataTable 3
Putative IC/BPS biomarkers (negative ESI) identiﬁed by PCA-DA loadings.
Masses (m/z) for candidatemolecules are shown alongwith their retention
time in minutes.
Metabolite (m/z) Retention time (min)
175.2 17.9
212.2 2.6
379.2 5.8
369.4 18.0
243.3 24.9
181.2 7.6
Fig. 2. Targeted analysis conﬁrms urinary etiocholan-3a-ol-17-one sulfate as a IC/BPS subgroup biomarker. (a) Targeted analysis reveals a signiﬁcantly higher ratio ofm/z 36918 to m/z
36920 in IC/BPS subgroup 2 compared to subgroup 1 andnon-IC/BPS controls (p=0.0003 and 0.0022, respectively, t-test). Likewise, levels ofm/z 369were higher in subgroup 1 compared
to non-IC/BPS controls (p=0.0071, t-test). (b)High-resolution positive ion ESImass spectrum is consistentwith the empiric formula C19H30O5S for a [M−H]− specieswith a difference of
−2.18 ppm. (c) High-resolution negative ion tandem ESI spectrum of the candidate biomarker is consistent with the empiric formula C19H30O5S ([M− H]− atm/z 369.1745) that frag-
ments to give a peak at m/z 96.9597, consistent with the presence of a sulfate group with the empiric formula SO4H. (d) Matching GC-EI-MS spectra of this sulfatase-treated, TMS-
derivatized analyte compared to a commercially available reference standard. Retention time for both the analyte and standard was 21.8 min.
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etiocholan-3α-ol-17-one (Etio-S), a testosterone derivative.
3.4. Etio-S Reliably Classiﬁes IC/BPS Specimens
To determine whether urinary Etio-S levels can accurately re-
solve IC/BPS from non-IC/BPS specimens, we used the discovery
dataset to construct a Receiver-Operator Characteristic (ROC)
curve. This analysis indicates that urinary Etio-S is a sensitive andFig. 3.Urinary Etio-S is associatedwith IC/BPS subjects. (a) ROC curve analysis on the discovery
area under the curve (AUC) value of 0.87 is statistically signiﬁcant from the null hypothesis (p
scores. These results were conﬁrmed in three independent experiments.speciﬁc IC/BPS marker, with an area under the curve (AUC) of
0.87 (p b 0.001, Fig. 3a). To conﬁrm these results, we assessed its
predictive value in a separate blinded specimen set composed of
forty female IC/BPS samples and forty healthy samples that were
not used in the discovery set or for model training (referred to
here as the ‘validation’ set). Etio-S was more highly associated
with IC/BPS in the validation set (AUC of 0.92, p b 0.0001; Fig. 3b).
Elevated Etio-S is a successful predictor of IC/BPS specimens in
the validation set, with a speciﬁcity of 87.4% and sensitivity ofset of 40 healthy participants and 40 IC/BPS participants' Etio-S levels and GUPI scores. The
b 0.001). (b) ROC curve analysis on validation samples using urine Etio-S levels and GUPI
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S levels can classify IC/BPS subjects with high accuracy.
3.5. Urinary Sulfometabolites Distinguish IC/BPS Subjects From Non-IC/BPS
Controls
Metabolomic associations with IC/BPS raise the possibility that Etio-
S may be the most detectable urinary manifestation of an extended,
multistep biochemical pathway. We hypothesized that metabolomic
proﬁling of urinary molecules that share Etio-S's distinctive sulfate
group might better resolve IC/BPS subjects from non- IC/BPS controls.
We therefore reconﬁgured our tandemmass spectrometer to selectively
detect other similarly sulfoconjugated, non-aromatic urinarymolecules.
Speciﬁcally, we conducted a precursor scan in which only molecules
that undergo MS/MS fragmentation to produce anm/z 97 ion (SO4H−)
are detected (Fig. 4a). This distinctive negative ion fragmentation is
characteristic of sulfated allylic or benzylic alcohols and aliphatic alco-
hols or enols, and can be used to distinguish alicyclic sulfates from aro-
matic sulfates (Shields-Cutler et al., 2015; Yi et al., 2006) (Fig. 4b). The
resulting PCA-DA analysis of urinary sulfometabolomes resolved IC/
BPS and non-IC/BPS individuals more completely (Fig. 4c) than the ini-
tial full scan (LC–MS) analysis (Fig. 1a). This urinary sulfometabolomic
resolution of IC/BPS subjects is remarkably evident in the D1 loading pa-
rameter, which corresponds tomultiplemetabolites in the loadings plot
(Fig. 4d). Together these data show that IC/BPS subjects exhibit stereo-
typical shifts in multiple sulfoconjugated urinary metabolites.
3.6. IC/BPS-associated Sulfometabolite Shifts are Longitudinally Sustained
To determine whether IC/BPS -associated sulfometabolomic shifts
are transient or persistent, we compared IC/BPS urinary
sulfometabolomes for the female ‘discovery’ cohort at enrollment to
their follow-up visits. Referred to here as the ‘longitudinal’ dataset,
this group consisted of 6- and 12-month time points for IC/BPS partici-
pants only. The distinctive sulfometabolomic shift in IC/BPS subjects
was sustained upon follow up, with subgroup 2 subjects remainingFig. 4. IC/BPS participants exhibit urinary sulfometabolomic shifts. (a) Representative MS–MS s
scan was designed to yield ametabolomic dataset selective for sulfoconjugatedmetabolites. (b)
DA plot comparing the differences in sulfoconjugatedmetabolites from IC/BPS and control urine
distribution of values from the loading plot arising from shifts in multiple sulfoconjugated moldistinctive from subgroup 1 (Fig. 5a and b). Etio-S levels similarly distin-
guished subgroup 1 and 2 subjects at longitudinal timepoints, suggest-
ing that metabolite levels are broadly representative of
sulfometabolome differences (Supplemental Fig. 2). Together, these
ﬁndings are consistent with Etio-S as a readily measured urinary corre-
late of multiple biochemical changes in highly symptomatic IC/BPS
subjects.
4. Discussion
Here we have used a metabolomics-based analytical platform to
seekmolecular correlates of IC/BPS from urine derived from female par-
ticipants. This metabolomic analysis resolved a phenotypic subgroup of
high symptom IC/BPS subjects with distinctive urinary levels of
etiocholan-3α-ol-17-one sulfate (Etio-S), a steroid metabolite. In longi-
tudinal studies, this IC/BPS-associated molecular signature persisted
through twelve months of participant follow up. Urinary Etio-S and re-
lated sulfometabolites may be diagnostically useful and may also serve
as a useful insight into pathophysiologic processes that contribute to
IC/BPS symptoms.
Etio-S is a 5-β reduced androstane metabolite of testosterone
(Slaunwhite and Sandberg, 1958), not previously reported as an IC/
BPS biomarker. Its unexpected association with a IC/BPS patient sub-
group exhibiting high extra-urinary symptoms (Table S1) is consistent
with, though not proof of, a connection to the disease process. Etio-S ap-
pears in the urine following hepatic sulfoconjugation of etiocholan-3α-
ol-17-one (Falany, 1991). Longitudinal metabolite differences between
IC/BPS subgroups may reﬂect differences in diet, lifestyle, or hepatic ac-
tivity. It is unclear whether etiocholan-3α-ol-17-one and its associated
metabolites directly affect IC/BPS symptoms or are indirect markers of
another disease process. Further investigation of theseﬁndings in an ex-
perimental study design may address these questions.
Although the mechanistic relationship between Etio-S and IC/BPS
remains to be deﬁned, the implication of a bioactive steroid in IC/BPS
symptoms is notable and suggests a possible causative mechanism.
High local etiocholan-3α-ol-17-one concentrations can stimulate acan of Etio-S indicates loss of a sulfate group atm/z 97. Using this information, a precursor
The characteristicm/z 97 loss, generated by sulfoconjugated aliphatic alcohols. (c) A PCA-
s shows the distinct differences in the urinary sulfometabolome of IC/BPS subjects. (d) The
ecules. These results were conﬁrmed in three independent experiments.
Fig. 5. IC/BPS associated sulfometabolomic shifts are temporally sustained. (a) Proﬁling sulfoconjugated urinarymolecules reveals persistent long-term IC/BPS-associatedmetabolic shifts.
The PCA-DAplot indicates that themetabolic shifts in the IC/BPS sulfometabolome are sustainedat longitudinal timepoints. (b)Values from theD1 loadings plot show thatmetabolic shifts
in the urinary sulfometabolome can stratify subjects into subgroups, indicating its correlative capacity for IC/BPS. Each data point represents the average of triplicate runs.
173K.S. Parker et al. / EBioMedicine 7 (2016) 167–174variety of acute phase responses (Wilmore, 1986), including inﬂamma-
tion, fever, leukocytosis, increased serum C-reactive protein, and in-
creased plasma interleukin-1 activity. In addition to these
inﬂammatory effects, Etio-S also acts as a positive allosteric modulator
of the GABAA receptor (Li et al., 2007). As GABAA receptors are ubiqui-
tously expressed throughout the central nervous system, changes in
Etio-S levels may physiologically manifest as the acute stress (Reddy,
2003), depression (Fujii and Mellon, 2001) and changes in nociception
(Drouet et al., 2015)that are often reported by IC/BPS patients. Intrigu-
ingly, sex-matched murine experiments indicate that sulfation activity
is higher in females and exhibits a different range of substrates (Singer
et al., 1976; Mulder, 1986). Combined with the observation that etio-
cholanolone accumulates in higher levels in female urine (Zumoff and
Bradlow, 1980), these metabolic shifts could contribute to higher IC/
BPS incidence in females.
As a proof of concept pilot study, this report is inherently limited by
the sample sizes associated with the discovery and validation groups.
The sample sizes are further constrained by the discovery of sub-
groups, which indicate that all IC/BPS samples cannot be uniformly
assessed by phenotypic criteria alone. The correlation between Etio-S
levels was strongest in samples with high symptoms scores, which
may limit themolecule's utility as a diagnostic tool for patients who re-
port lower scores in the metrics examined in this study. The results re-
ported here warrant larger validation studies, and should be expanded
to determine whether similar biochemical shifts can be linked to the
UCPPS phenotypes in males.
There is a longstanding need to identify biochemical correlates of IC/
BPS. Despite its high prevalence and debilitating burden, no organ-
speciﬁc disease, pathognomonic ﬁndings, deﬁnitive disease pheno-
types, or objective biomarkers have been conclusively identiﬁed. Clini-
cal diagnosis is based primarily on subjective symptom reporting by
patients and exclusion of other conditions. There has been no objective
way to deﬁnitively distinguish the disease from other overlapping con-
ditions, or to identify meaningful IC/BPS patient subgroups (phenotyp-
ing), frustrating both clinical management and therapeutic
development. By combiningmetabolomics-based discovery with inten-
sive longitudinal clinical phenotyping analysis of a representative pa-
tient population, we have identiﬁed candidate biochemical markers
linked to symptom-based subgroups. The metabolites identiﬁed in this
studymay complement ongoing attempts to identify IC/BPS biomarkers
and underlying etiology through by proteomic methods (Dimitrakov
and Guthrie, 2009), brain imaging (Bagarinao et al., 2014), and inﬂam-
matory marker quantiﬁcation (Schrepf et al., 2015; Schrepf et al.,
2014). By combining results from these approaches, we may map the
early biochemical changes associatedwith heterogeneous IC/BPS symp-
toms and develop predictive biomarkers that can trigger earlier
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